COMMUNIQUÉS West-GlobeNewswire

AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
15/06/2026
OCALA, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM,” or the “Company”), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, [...]
Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing
15/06/2026
Board expansion from six to nine directors and the appointment of a Chief Commercial Officer and an advisory board member to help accelerate growth and strengthen execution RENO, Nev., June 15, 2026 (GLOBE NEWSWIRE) -- [...]
Fate Therapeutics Appoints Laura Hamill to Board of Directors
15/06/2026
Accomplished global commercial operations leader brings deep experience launching and scaling biopharmaceutical products as Fate advances its pipeline toward commercialization SAN DIEGO, June 15, 2026 (GLOBE NEWSWIRE [...]
Immuneering Appoints Andrew Gengos as Chief Financial Officer
15/06/2026
- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Immuneering [...]
Cannabix Technologies Announces Deployment of Marijuana Breath Test (MBT) with Major Industrial Operator in Quebec
15/06/2026
VANCOUVER, British Columbia, June 15, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing [...]
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
15/06/2026
MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) OPKO Biologics, an OPKO Health company, presented preclinical data for OPK8801001 at ENDO 2026, the Endocrine Society’s annual meeting. The poster [...]
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
15/06/2026
New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker’s protective barrier function Raanana, Israel [...]
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
15/06/2026
IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment AUSTIN, Texas, June 15, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today [...]
Aerska Strengthens Board with Appointments of Uli Stilz and Itziar Canamasas
15/06/2026
DUBLIN and LONDON, 15 June 2026 -- Aerska, a biotechnology company using brain shuttle technology to develop RNA medicines for CNS diseases, today announces the appointment of Itziar Canamasas and Uli Stilz to the [...]
Sienna Announces June Dividend
15/06/2026
MARKHAM, Ontario, June 15, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
15/06/2026
– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston – – Women who received Humacyte's ATEV experienced an average of three more months [...]
XBiotech lance un essai clinique de phase II visant à évaluer le vilamakitug dans le traitement de la spondylarthrite axiale active
15/06/2026
La demande d’IND pour l’étude V-SPINE a fait l’objet d’un examen de 30 jours par la FDA sans suspension clinique, ouvrant ainsi la voie au recrutement de patients aux États-Unis AUSTIN, Texas, 15 juin 2026 (GLOBE [...]
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
15/06/2026
Submission Supports Development of a Potential Non-Surgical Treatment for a Rare Genetic Disorder that Causes Recurrent Basal Cell Carcinomas Beginning in Childhood PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- [...]
Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
15/06/2026
The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S. FESILTY complements Grifols’ bleeding [...]
Sparrow Pharmaceuticals Announces Interim CAPTAIN-T2D Data Validating High Prevalence of Elevated Cortisol in Difficult-to-Control Type 2 Diabetes
15/06/2026
More than 75% of patients screened show elevated cortisol level associated with increased prevalence of cardiovascular disease Inadequate glycemic control despite incretin mimetic use and concomitant hypertension were [...]
Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum
15/06/2026
SOUTH SAN FRANCISCO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery [...]
Integra LifeSciences to Present at the 2026 Truist Securities MedTech Conference
15/06/2026
PRINCETON, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Bob Davis, executive vice president and [...]
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
15/06/2026
New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussions Additional billion-dollar target- Cardiac Surgery-Associated Acute Kidney Injury [...]
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
15/06/2026
SPY002 met its primary endpoint with a statistically significant reduction of 10.7 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score Secondary endpoints included clinical [...]

Pages